OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE
- Product NDC
- 50228-342
- Requested package NDC
- 50228-342-10
- 11-digit product format
- 502280342
- Labeler code
- 50228
- Product ID
- 50228-342_54de565a-a0f2-c621-e063-6394a90a9dae
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- ScieGen Pharmaceuticals Inc
- Application
- ANDA208465
- Marketing category
- ANDA
- Marketing start
- 2026-05-19
- Substance
- OLMESARTAN MEDOXOMIL; HYDROCHLOROTHIAZIDE
- Active strength
- 20; 12.5 mg/1; mg/1
- Pharmacologic classes
- Angiotensin 2 Receptor Antagonists [MoA], Angiotensin 2 Receptor Blocker [EPC], Increased Diuresis [PE], Thiazide Diuretic [EPC], Thiazides [CS]
- NDC exclude flag
- No
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A208465-001 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL | 12.5MG;20MG | TABLET / ORAL | AB | 2026-03-31 | |
| A208465-002 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL | 12.5MG;40MG | TABLET / ORAL | AB | 2026-03-31 | |
| A208465-003 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL | 25MG;40MG | TABLET / ORAL | AB | 2026-03-31 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A208465-001 | AB |
| A208465-002 | AB |
| A208465-003 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A208465-001 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;20MG | TABLET / ORAL | AB | 2026-03-31 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A208465-002 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;40MG | TABLET / ORAL | AB | 2026-03-31 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | A208465-003 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 25MG;40MG | TABLET / ORAL | AB | 2026-03-31 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | A208465-001 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;20MG | TABLET / ORAL | AB | 2026-03-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A208465-002 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;40MG | TABLET / ORAL | AB | 2026-03-31 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A208465-003 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 25MG;40MG | TABLET / ORAL | AB | 2026-03-31 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-001 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;20MG | TABLET / ORAL | AB | 2026-03-31 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-002 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 12.5MG;40MG | TABLET / ORAL | AB | 2026-03-31 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-003 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 25MG;40MG | TABLET / ORAL | AB | 2026-03-31 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A208465-001 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A208465-002 | AB | 1 | 84e616aacf4f… |
| 2026-09-14 22:38:34 | 2026-08 | A208465-003 | AB | 1 | 84e616aacf4f… |
| 2026-08-18 06:07:40 | 2026-07 | A208465-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A208465-002 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A208465-003 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-002 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A208465-003 | AB | 1 | a50c72e98297… |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| OLMESARTAN MEDOXOMIL | 20 mg/1 |
| HYDROCHLOROTHIAZIDE | 12.5 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 6M97XTV3HD | Internal UNII lookup |
| 0J48LPH2TH | Internal UNII lookup |
Harmonized RxCUI identifiers#
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 52332190-2a12-d205-e063-6394a90ab7c5 | Available on FDA.report |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | Golden State Medical Supply, Inc. | 574d2679-c036-fa12-e063-6394a90aef33 | 2026-07-23 | Boxed warning, Warnings, Adverse reactions | 208465 ANDA208465 |
| OLMESARTAN MEDOXOMIL and HYDROCHLOROTHIAZIDE | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | ScieGen Pharmaceuticals Inc | 52332190-2a12-d205-e063-6394a90ab7c5 | 2026-05-22 | Boxed warning, Warnings, Adverse reactions | 208465 ANDA208465 50228-342-10 50228-342 50228034210 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|
| 50228-342-10 | 50228034210 | 1000 TABLET, FILM COATED in 1 BOTTLE (50228-342-10) | 2026-05-19 | No | No | Current |